Lunai Bioworks Inc. SEC filings LNAI
Lunai Bioworks Inc. has 599 filings in SEC EDGAR's recent list, going back to Aug 12, 2011. Its latest annual report, Form 10-K, was filed on Oct 13, 2026 for the period ended Jun 30, 2026. The latest quarterly report (Form 10-Q) was filed on May 15, 2026, covering the quarter ended Mar 31, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (listing notice, officer or director change, regulation fd disclosure, other events). The company's fiscal year ends on June 30.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 28, 2026 | — |
| DEF 14A | Proxy statement | Apr 13, 2026 | Apr 13, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 2, 2026 | Apr 2, 2026 |
| DEF 14A | Proxy statement | Oct 15, 2025 | Oct 15, 2025 |
| DEF 14A | Proxy statement | Jul 30, 2025 | Jul 30, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 18, 2025 | Jul 18, 2025 |
| DEFA14A | Additional proxy material | Jan 16, 2024 | — |
| DEFA14A | Additional proxy material | Jan 16, 2024 | — |
| DEFM14A | Form defm14a | Jan 3, 2024 | — |
| PREM14A | Filing | Dec 22, 2023 | Dec 22, 2023 |
| DEFA14A | Additional proxy material | Dec 22, 2023 | — |
| DEFA14A | Additional proxy material | Dec 11, 2023 | — |
| DEFA14A | Additional proxy material | Dec 7, 2023 | — |
| DEFA14A | Additional proxy material | Dec 1, 2023 | — |
| DEFA14A | Additional proxy material | Dec 1, 2023 | — |
| DEFA14A | Additional proxy material | Nov 22, 2023 | — |
| DEFA14A | Additional proxy material | Nov 2, 2023 | — |
| DEFA14A | Additional proxy material | Oct 11, 2023 | — |
| DEFA14A | Additional proxy material | Oct 10, 2023 | — |
| DEFA14A | Additional proxy material | Oct 4, 2023 | — |
| DEFA14A | Additional proxy material | Oct 4, 2023 | — |
| DEFA14A | Additional proxy material | Jul 10, 2023 | — |
| DEFA14A | Additional proxy material | Jun 23, 2023 | — |
| DEF 14A | Proxy statement | May 16, 2023 | May 15, 2023 |
| DEFA14A | Additional proxy material | Jan 28, 2022 | — |
| DEFA14A | Additional proxy material | Jan 28, 2022 | — |
| DEF 14A | Proxy statement | Jan 27, 2022 | Jan 28, 2022 |
| DEF 14A | Proxy statement | Feb 3, 2021 | Mar 5, 2021 |
| DEF 14A | Proxy statement | May 22, 2020 | Jun 24, 2020 |
| DEF 14C | Information statement | Nov 12, 2019 | Nov 18, 2019 |
| PRE 14C | Filing | Nov 1, 2019 | Nov 1, 2019 |
| DEF 14A | Proxy statement | Nov 21, 2016 | Dec 6, 2016 |
| PRE 14A | Preliminary proxy statement | Oct 4, 2016 | Oct 3, 2016 |
| DEF 14A | Proxy statement | Dec 1, 2015 | Jan 8, 2016 |
| DEF 14C | Information statement | Feb 18, 2014 | Feb 17, 2014 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LNAI (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- DE
- Headquarters
- Suite 906 Los Angeles, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1527728
- Former names
- RENOVARO INC. (until Aug 26, 2025); RENOVARO BIOSCIENCES INC. (until Feb 7, 2024); Enochian Biosciences Inc (until Aug 1, 2023); DanDrit Biotech USA, Inc. (until Feb 23, 2018); Putnam Hills Corp. (until Feb 11, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.